These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11304903)

  • 1. Effect of alosetron on the pharmacokinetics of fluoxetine.
    D'Souza DL; Dimmitt DC; Robbins DK; Nezamis J; Simms L; Koch KM
    J Clin Pharmacol; 2001 Apr; 41(4):455-8. PubMed ID: 11304903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of alosetron on the pharmacokinetics of alprazolam.
    D'Souza DL; Levasseur LM; Nezamis J; Robbins DK; Simms L; Koch KM
    J Clin Pharmacol; 2001 Apr; 41(4):452-4. PubMed ID: 11304902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
    Houghton LA; Foster JM; Whorwell PJ
    Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
    Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
    Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
    Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alosetron.
    Balfour JA; Goa KL; Perry CM
    Drugs; 2000 Mar; 59(3):511-8; discussion 519-20. PubMed ID: 10776833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: clinical pharmacology of alosetron.
    Gunput MD
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
    Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM
    Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
    Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
    Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex).
    Koch K; Campanella C; Baidoo CA; Manzo JA; Ameen VZ; Kersey KE
    Dig Dis Sci; 2004 Aug; 49(7-8):1244-9. PubMed ID: 15387353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.
    Bush TG; Spencer NJ; Watters N; Sanders KM; Smith TK
    Am J Physiol Gastrointest Liver Physiol; 2001 Oct; 281(4):G974-83. PubMed ID: 11557518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an indian population perspective. Retrospective pharmacokinetic data evaluation.
    Kandasamy M; Tripathy K; Ravi S; Kamath N; Pai B; Srinivas NR; Kristjansson F; Thangam S
    Arzneimittelforschung; 2010; 60(1):12-21. PubMed ID: 20184222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
    Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
    Camilleri M; Mayer EA; Drossman DA; Heath A; Dukes GE; McSorley D; Kong S; Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1149-59. PubMed ID: 10468696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of alosetron on theophylline pharmacokinetics.
    Koch KM; Ricci BM; Hedayetullah NS; Jewell D; Kersey KE
    Br J Clin Pharmacol; 2001 Nov; 52(5):596-600. PubMed ID: 11736869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
    Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
    Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
    Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
    Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
    Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and clinical experience with alosetron.
    Camilleri M
    Expert Opin Investig Drugs; 2000 Jan; 9(1):147-59. PubMed ID: 11060667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
    Cremonini F; Delgado-Aros S; Camilleri M
    Neurogastroenterol Motil; 2003 Feb; 15(1):79-86. PubMed ID: 12588472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.